Even before the COVID-19 pandemic, health departments had limited staff, resources and time to support the diverse public health needs of our communities. This system will be further strained as the epidemic grows. We must immediately create a national public health reserve to shore up public health systems.
Things are still getting worse. The US death toll crossed 14,000 on Wednesday, with a record 1,858 deaths reported just on Tuesday. Since the outbreak started, about 425,000 cases have been diagnosed in the US. And researchers say the peak has yet to come.
The Coler Lab at Seattle Children’s Research Institute is using their expertise to support the clinical trial of an experimental coronavirus vaccine funded by National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. The trial is being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle, part of NIAID’s Infectious Diseases Clinical Research Consortium.
The benefits of hydroxychloroquine being investigated in multi-site clinical trial launching in April
Researchers are investigating whether hydroxychloroquine – a commonly used anti-malarial and autoimmune drug – can prevent COVID-19.
A multi-site clinical trial, led by the University of Washington Department of Global Health/International Clinical Research Center (ICRC) in collaboration with NYU Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.
In a forecast based on new data analyses, researchers find demand for ventilators and beds in US hospital intensive care units (ICUs) will far exceed capacity for COVID-19 patients as early as the second week of April. Deaths related to the current wave of COVID-19 in the US are likely to persist into July, even assuming people protect themselves and their communities by strongly adhering to social distancing measures and by taking other precautions advised by public health officials.
While pregnant women are included in those thought to be at high risk for COVID-19, not much is actually known yet about the virus' potential impacts on pregnancy.
But a University of Washington obstetrician and professor hopes to change that, shifting her lab's research into the new virus.
As lockdowns sweep the country and people prepare to work from home for months, many are wondering whether springtime’s warmer temperatures will provide much-needed relief from the coronavirus. Others, including President Donald Trump, have made the case that it’s a certainty.
When we asked you to submit questions for three Seattle-area leaders about the COVID-19 pandemic, you responded in droves.
In less than 24 hours, Seattle Times readers submitted more than 400 questions for our video interview Thursday with our three panelists:
Seattle’s Infectious Disease Research Institute has received seven-figure funding to begin human trials on a potentially groundbreaking novel coronavirus treatment.
The study could launch within weeks, take about 11 months to complete, and enroll about 100 patients diagnosed with a COVID-19 infection that’s causing moderate to severe pneumonia. It would deploy cancer-fighting NK-cells as an immunotherapy treatment for the coronavirus rather than the current approach of antiviral medication.
Patricia García, Peru's former Minister of Health and an Affiliate Professor of Global Health at the University of Washington, spoke to Publimetro in her home country of Peru about the country's response to the coronavirus pandemic. García received a Masters of Public Health at UW and is also a professor at the School of Public Health at Cayetano Heredia University in Lima, Peru. Her areas of expertise include epidemiology, infectious diseases, and implementation science.
The following interview has been translated from Spanish.